Global Head and Neck Cancer Therapeutics Market by Therapeutic Class (EGFR Inhibitors, Microtubule Inhibitors, PD Inhibitors) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Industry Insights
Global head and neck cancer therapeutics market was worth USD 752.5 million in 2016. It is expected to grow at 9.4% CAGR during the forecast period. Current treatment options for head and neck cancer include surgery, radiation therapy and chemotherapy. Based on promising clinical results, immunotherapies are now being promoted as a precision medicine approach to managing solid malignancies. Anemia, neutropenia and nausea, vomiting, pain and bone metastasis are some of the side effects that can be caused by head and neck cancer treatment.
According to the Union for International Cancer Control, (UICC), 550,000 are diagnosed with neck and head cancer each year. 300,000. deaths are also recorded annually. Head and neck cancer was the sixth most prevalent cancer in 2016, accounting for 5.0% of all global cancers. Squamous cell carcinomas (SCCHN) account for 90.0% of head and neck cancers. This condition is more common in men than it is in women. It can be found in a ratio of 2:1 to 1:1.
Opportunities for market expansion are being identified in Brazil, India, China and China. These countries are attracting market expansion due to factors such as the growing use of Biosimilars, good healthcare reforms and a low-cost base.
According to current trends, the market will be driven by a growing geriatric population, increasing cases of target diseases and improved healthcare services thanks to initiatives from government and private organizations. Players have the opportunity to profit from and expand in other countries due to increased immunotherapy adoption. PD inhibitors will likely capture a large market share and increase overall franchise revenue.
More than 43 products are currently in clinical trials for the head and neck cancer therapeutics industry. Although early-stage cancers can be curable, treatment depends on the type of the disease, its location and severity. The latest surgical and nonsurgical treatments, such as targeted therapy and immunotherapy, allow for the preservation of quality of life and provide the best care.
Recent advancements in cancer research have allowed for the successful treatment of patients' own immune systems. During the forecast period, major pipeline drugs like Imfinzi (durvalumab), and Bavencio ("avelumab") are expected to be released. These drugs' clinical trials have shown positive results for both primary and secondary endpoints.
Therapeutic Class Insights
Microtubule inhibitors and PD inhibitors are the most prominent drug classes in the market for head and neck cancer therapeutics. In 2016, PD inhibitors accounted the largest market share, followed closely by EGFR inhibits. New product launches are expected to drive significant growth in the PD inhibitor drug category. Due to the high adoption of targeted therapies and immunotherapies, the market share of EGFR inhibitors as well as microtubule inhibitions will decline by a double-digit percentage over the forecast period.
There are several major brands that are prescribed for head and neck cancer: Opdivo (nivolumab) by Bristol-Myers Squibb, Merck's Keytruda(pembrolizumab), Eli Lilly’s Erbitux (“cetuximabâ€Â) by Sanofi and Taxotere® (docetaxel).
Regional Insights
Global demand for neck and head cancer drugs will be driven by increasing SCCHN incidence, side effects of chemotherapy and radiation therapy, the development of cost-effective therapies, higher healthcare expenditure, better government policies and reimbursement policies, as well as rising SCCHN rates.
The U.S. was the dominant market leader in 2016 with more than 50% of the global market. Japan has seen an increase in immunotherapies adoption and is forecast to show a CAGR (or 4.9%) during the forecast period.
Market Share in Head and Neck Cancer Therapeutics
Merck & Co. Eli Lilly, Sanofi and Merck Group are some of the major players in this sector. AstraZeneca's approval of Imfinzi, and Bavencio will create significant market opportunities for Pfizer and AstraZeneca during the forecast period. Marsala Biotech, Marsala Biotech, and Kura Oncology are some of the promising companies that have pipeline drugs.
Many companies have been affected by patent expirations and increased biosimilar competition, including Sanofi and Eli Lilly. Actavis and Jiangsu Hengrui are the main players in manufacturing biosimilar Taxotere or Erbitux. Many market players will be working to address unmet market demands, identify new targets, and develop stronger drug pipelines.
The Report Covers Certain Segments
This report provides a forecast of revenue growth at the country and regional levels, as well as an analysis of industry trends in each sub-segment from 2016 to 2022. Up Market Research has divided the global head-and neck cancer therapeutics market report by therapeutic class and region.
-
Therapeutic Class Outlook (Revenue USD Million, 2016-2022)
-
PD Inhibitors
-
EGFR Inhibitors
-
Microtubule Inhibitors
-
-
Regional Outlook (Revenue USD Million, 2016-2022)
-
The U.S.
-
The U.K.
-
France
-
Germany
-
Italy
-
Spain
-
Japan
-
Up Market Research published a new report titled “Head and Neck Cancer Therapeutics Market research report which is segmented by Therapeutic Class (EGFR Inhibitors, Microtubule Inhibitors, PD Inhibitors), By Players/Companies EGFR inhibitors, microtubule inhibitors Among these therapeutic classes, PD inhibitors accounted for the largest market share in 2016, primarily driven by new product launches The market shares of EGFR inhibitors and microtubule inhibitors will see a double-digit decline over the course of the forecast period owing to high adoption of immunotherapies and targeted therapies, PD inhibitors, followed by EGFR inhibitors The PD inhibitor drug class is expected to grow significantly throughout the forecast period”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Head and Neck Cancer Therapeutics Market Research Report |
| By Therapeutic Class | EGFR Inhibitors, Microtubule Inhibitors, PD Inhibitors |
| By Companies | EGFR inhibitors, microtubule inhibitors Among these therapeutic classes, PD inhibitors accounted for the largest market share in 2016, primarily driven by new product launches The market shares of EGFR inhibitors and microtubule inhibitors will see a double-digit decline over the course of the forecast period owing to high adoption of immunotherapies and targeted therapies, PD inhibitors, followed by EGFR inhibitors The PD inhibitor drug class is expected to grow significantly throughout the forecast period |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 248 |
| Number of Tables & Figures | 174 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Head and Neck Cancer Therapeutics Market Report Segments:
The market is segmented by Therapeutic Class (EGFR Inhibitors, Microtubule Inhibitors, PD Inhibitors).
Head and Neck Cancer Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Head and Neck Cancer Therapeutics Market
Overview of the regional outlook of the Head and Neck Cancer Therapeutics Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Head and Neck Cancer Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Head and Neck Cancer Therapeutics Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. EGFR Inhibitors
2. Microtubule Inhibitors
3. PD Inhibitors
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Head and Neck Cancer Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Head and Neck Cancer Therapeutics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Head and Neck Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Head and Neck Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Head and Neck Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Head and Neck Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Head and Neck Cancer Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Head and Neck Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Head and Neck Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Head and Neck Cancer Therapeutics Market Analysis and Forecast by Therapeutic Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapeutic Class
5.1.2 Basis Point Share (BPS) Analysis by Therapeutic Class
5.1.3 Absolute $ Opportunity Assessment by Therapeutic Class
5.2 Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
5.2.1 EGFR Inhibitors
5.2.2 Microtubule Inhibitors
5.2.3 PD Inhibitors
5.3 Market Attractiveness Analysis by Therapeutic Class
Chapter 6 Global Head and Neck Cancer Therapeutics Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Head and Neck Cancer Therapeutics Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Head and Neck Cancer Therapeutics Analysis and Forecast
8.1 Introduction
8.2 North America Head and Neck Cancer Therapeutics Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
8.6.1 EGFR Inhibitors
8.6.2 Microtubule Inhibitors
8.6.3 PD Inhibitors
8.7 Basis Point Share (BPS) Analysis by Therapeutic Class
8.8 Absolute $ Opportunity Assessment by Therapeutic Class
8.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 9 Europe Head and Neck Cancer Therapeutics Analysis and Forecast
9.1 Introduction
9.2 Europe Head and Neck Cancer Therapeutics Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
9.6.1 EGFR Inhibitors
9.6.2 Microtubule Inhibitors
9.6.3 PD Inhibitors
9.7 Basis Point Share (BPS) Analysis by Therapeutic Class
9.8 Absolute $ Opportunity Assessment by Therapeutic Class
9.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 10 Asia Pacific Head and Neck Cancer Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Head and Neck Cancer Therapeutics Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
10.6.1 EGFR Inhibitors
10.6.2 Microtubule Inhibitors
10.6.3 PD Inhibitors
10.7 Basis Point Share (BPS) Analysis by Therapeutic Class
10.8 Absolute $ Opportunity Assessment by Therapeutic Class
10.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 11 Latin America Head and Neck Cancer Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Latin America Head and Neck Cancer Therapeutics Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
11.6.1 EGFR Inhibitors
11.6.2 Microtubule Inhibitors
11.6.3 PD Inhibitors
11.7 Basis Point Share (BPS) Analysis by Therapeutic Class
11.8 Absolute $ Opportunity Assessment by Therapeutic Class
11.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 12 Middle East & Africa (MEA) Head and Neck Cancer Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Head and Neck Cancer Therapeutics Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
12.6.1 EGFR Inhibitors
12.6.2 Microtubule Inhibitors
12.6.3 PD Inhibitors
12.7 Basis Point Share (BPS) Analysis by Therapeutic Class
12.8 Absolute $ Opportunity Assessment by Therapeutic Class
12.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 13 Competition Landscape
13.1 Head and Neck Cancer Therapeutics Market: Competitive Dashboard
13.2 Global Head and Neck Cancer Therapeutics Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 EGFR inhibitors
13.3.2 microtubule inhibitors Among these therapeutic classes
13.3.3 PD inhibitors accounted for the largest market share in 2016
13.3.4 primarily driven by new product launches The market shares of EGFR inhibitors and microtubule inhibitors will see a double-digit decline over the course of the forecast period owing to high adoption of immunotherapies and targeted therapies
13.3.5 PD inhibitors
13.3.6 followed by EGFR inhibitors The PD inhibitor drug class is expected to grow significantly throughout the forecast period
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Head and Neck Cancer Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Head and Neck Cancer Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Head and Neck Cancer Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Head and Neck Cancer Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Head and Neck Cancer Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Head and Neck Cancer Therapeutics Market Size and Y-o-Y Growth
4.5.2 Head and Neck Cancer Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Head and Neck Cancer Therapeutics Market Analysis and Forecast by Therapeutic Class
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Therapeutic Class
5.1.2 Basis Point Share (BPS) Analysis by Therapeutic Class
5.1.3 Absolute $ Opportunity Assessment by Therapeutic Class
5.2 Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
5.2.1 EGFR Inhibitors
5.2.2 Microtubule Inhibitors
5.2.3 PD Inhibitors
5.3 Market Attractiveness Analysis by Therapeutic Class
Chapter 6 Global Head and Neck Cancer Therapeutics Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Head and Neck Cancer Therapeutics Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Head and Neck Cancer Therapeutics Analysis and Forecast
8.1 Introduction
8.2 North America Head and Neck Cancer Therapeutics Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
8.6.1 EGFR Inhibitors
8.6.2 Microtubule Inhibitors
8.6.3 PD Inhibitors
8.7 Basis Point Share (BPS) Analysis by Therapeutic Class
8.8 Absolute $ Opportunity Assessment by Therapeutic Class
8.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 9 Europe Head and Neck Cancer Therapeutics Analysis and Forecast
9.1 Introduction
9.2 Europe Head and Neck Cancer Therapeutics Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
9.6.1 EGFR Inhibitors
9.6.2 Microtubule Inhibitors
9.6.3 PD Inhibitors
9.7 Basis Point Share (BPS) Analysis by Therapeutic Class
9.8 Absolute $ Opportunity Assessment by Therapeutic Class
9.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 10 Asia Pacific Head and Neck Cancer Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Head and Neck Cancer Therapeutics Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
10.6.1 EGFR Inhibitors
10.6.2 Microtubule Inhibitors
10.6.3 PD Inhibitors
10.7 Basis Point Share (BPS) Analysis by Therapeutic Class
10.8 Absolute $ Opportunity Assessment by Therapeutic Class
10.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 11 Latin America Head and Neck Cancer Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Latin America Head and Neck Cancer Therapeutics Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
11.6.1 EGFR Inhibitors
11.6.2 Microtubule Inhibitors
11.6.3 PD Inhibitors
11.7 Basis Point Share (BPS) Analysis by Therapeutic Class
11.8 Absolute $ Opportunity Assessment by Therapeutic Class
11.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 12 Middle East & Africa (MEA) Head and Neck Cancer Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Head and Neck Cancer Therapeutics Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Head and Neck Cancer Therapeutics Market Size Forecast by Therapeutic Class
12.6.1 EGFR Inhibitors
12.6.2 Microtubule Inhibitors
12.6.3 PD Inhibitors
12.7 Basis Point Share (BPS) Analysis by Therapeutic Class
12.8 Absolute $ Opportunity Assessment by Therapeutic Class
12.9 Market Attractiveness Analysis by Therapeutic Class
Chapter 13 Competition Landscape
13.1 Head and Neck Cancer Therapeutics Market: Competitive Dashboard
13.2 Global Head and Neck Cancer Therapeutics Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 EGFR inhibitors
13.3.2 microtubule inhibitors Among these therapeutic classes
13.3.3 PD inhibitors accounted for the largest market share in 2016
13.3.4 primarily driven by new product launches The market shares of EGFR inhibitors and microtubule inhibitors will see a double-digit decline over the course of the forecast period owing to high adoption of immunotherapies and targeted therapies
13.3.5 PD inhibitors
13.3.6 followed by EGFR inhibitors The PD inhibitor drug class is expected to grow significantly throughout the forecast period
Segments Covered in the Report
The global Head and Neck Cancer Therapeutics market has been segmented based on
By Therapeutic Class
The global Head and Neck Cancer Therapeutics market has been segmented based on
By Therapeutic Class
- EGFR Inhibitors
- Microtubule Inhibitors
- PD Inhibitors
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- EGFR inhibitors
- microtubule inhibitors Among these therapeutic classes
- PD inhibitors accounted for the largest market share in 2016
- primarily driven by new product launches The market shares of EGFR inhibitors and microtubule inhibitors will see a double-digit decline over the course of the forecast period owing to high adoption of immunotherapies and targeted therapies
- PD inhibitors
- followed by EGFR inhibitors The PD inhibitor drug class is expected to grow significantly throughout the forecast period
Our Clients
Related Reports
Some other reports from this category!
